Long-term study of tubeless insulin pump therapy compared to multiple daily injections in youth with type 1 diabetes: Data from the German/Austrian DPV registry
Wissenschaftlicher Artikel
Authors
Danne, Thomas
Schwandt, Anke
Biester, Torben
Heidtmann, Bettina
Rami-Merhar, Birgit
Faculties
Medizinische FakultätInstitutions
Institut für Epidemiologie und Medizinische BiometriePublished in
Pediatric Diabetes ; 19 (2018), 5. - S. 979-984. - ISSN 1399-543X. - eISSN 1399-5448
Link to original publication
https://dx.doi.org/https://doi.org/10.1111/pedi.12658Peer review
ja
Document version
acceptedVersion
Abstract
Objective
To examine glycemic control in youth with type 1 diabetes (T1D) who switched from multiple daily injections (MDI) to a tubeless insulin pump (Omnipod Insulin Management System, Insulet Corporation, Billerica, Massachusetts) compared to patients who continued MDI therapy over a 3‐year time period.
Research Design and Methods
This retrospective analysis of the German/Austrian Diabetes Patienten Verlaufsdokumentation registry included data from 263 centers and 2529 patients <20 years (n = 660 tubeless insulin pump; n = 1869 MDI) who initiated treatment on a tubeless insulin pump as of January 1, 2013 and had 1 year of data preswitch from MDI and 3 years of data postswitch to a tubeless pump. Outcomes included the change in glycated hemoglobin (HbA1c), insulin dose, and body mass index (BMI) SD score (SDS).
Results
Youth with T1D who switched from MDI therapy to a tubeless insulin pump showed better glycemic control at 1 year compared to patients who continued MDI treatment, adjusted mean ± SE: 7.5% ± 0.03% (58 mmol/mol) vs 7.7% ± 0.02% (61 mmol/mol); P < .001, with no between‐group difference at 2 and 3 years. Total daily insulin dose was lower (P < .001) in the tubeless insulin pump group, 0.80 ± 0.01, 0.81 ± 0.01, and 0.85 ± 0.01 U/kg, vs the MDI group, 0.89 ± 0.01, 0.94 ± 0.01, and 0.97 ± 0.01 U/kg, at 1, 2, and 3 years, respectively (all P < .001). BMI SDS increased in both groups and was not different over time.
Conclusions
Treatment with a tubeless insulin pump in youth with T1D was associated with improvements in glycemic control compared to MDI after 1 year and appears to be an effective alternative to MDI.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Funding information
Leona M. and Harry B. Helmsley Charitable Trust
EFPIA
Deutsches Zentrum für Diabetesforschung (DZD)
European Foundation for the Study of Diabetes (EFSD)
Kompetenznetz Diabetes Mellitus - BMBF [FKZ 01GI1106]
etc.
EFPIA
Deutsches Zentrum für Diabetesforschung (DZD)
European Foundation for the Study of Diabetes (EFSD)
Kompetenznetz Diabetes Mellitus - BMBF [FKZ 01GI1106]
etc.
EU Project
INNODIA / Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes - Sofia ref.: 115797 / EC / H2020 / 115797
Subject Headings
Diabetes mellitus Typ 1 [GND]Insulinpumpe [GND]
Diabetes mellitus, Type 1 [MeSH]
Adolescent [MeSH]
Child [MeSH]
Insulin infusion systems [MeSH]
Keywords
CSII; HbA1c; MDIDewey Decimal Group
DDC 610 / Medicine & healthMetadata
Show full item recordCitation example
Danne, Thomas et al. (2020): Long-term study of tubeless insulin pump therapy compared to multiple daily injections in youth with type 1 diabetes: Data from the German/Austrian DPV registry. Open Access Repositorium der Universität Ulm. http://dx.doi.org/10.18725/OPARU-33920